Prospective evaluation of PI-RADS version 2.1 for clinically significant prostate cancer detection: Local performance at a University Hospital in Chile
Prospective evaluation of PI-RADS version 2.1 for clinically significant prostate cancer detection: Local performance at a University Hospital in Chile
Camilo G. Sotomayor; Baltasar Ramos; Camila González; Javier Cacho; Carla Parra; Juan Casas; Sebastián Yévenes; Gonzalo Cárdenas; Álvaro Sanhueza; Francisca Araya; Maximiliano Miranda
In Chile, prospective data of Prostate Imaging Reporting and Data System (PI-RADS) version 2.1 for prostate cancer detection has not been published. Thus, the local performance of PI-RADS version 2.1 for detection of clinically significant prostate cancer (csPCa) remains unknown. To evaluate lesion-based csPCa rates across different categories of PI-RADS version 2.1.
We performed a single-center prospective study of men with clinically suspected prostate cancer who underwent multiparametric magnetic resonance imaging (MRI) and MRI/ultrasound-guided biopsy between January 2022 and June 2023 at the Clinical Hospital University of Chile (Quality Control of Prostate MRI Programme). MRI scans were evaluated by body radiologists using PI-RADS version 2.1. Lesions with an International Society of Urological Pathology (ISUP) grade ≥2 (range 1–5) were considered csPCa. In each patient, the single lesion of highest PIRADS category was evaluated.
In total, 107 men (mean age, 65 ± 10 years). The csPCa rates for lesions categorized as PI-RADS 1 (n = 0), 2 (n = 1), 3 (n = 15), 4 (n = 45), and 5 (n = 17) were 0%, 0%, 14%, 44%, and 76%, respectively. csPCa rates of PI-RADS 4 lesions were significantly lower than PI-RADS 5 lesions but higher than PI-RADS 3 lesions (P < 0.05). csPCa rates of PI-RADS 3 lesions were significantly lower than PI-RADS 4 lesions but higher than PI-RADS 2 lesions (P < 0.05).
The rates of csPCa differed between consecutive PI-RADS categories of 2 and higher. This prospective study at a University Hospital in Chile supports that PI-RADS version 2.1 helps stratify participants according to their risk for csPCa.
